A chronic relapsing form ofexperimental autoimmune encephalomyelitis (CR-EAE) was induced in SJL/J mice by adoptive transfer of lymph node cells (LNC) sensitized to guinea pig myelin basic protein (GMBP). We examined the efficacy of high dose immunosuppressive regimens (cyclophosphamide ICY] 300 mg/kg or total body irradiation ITBI1 900 cGy) followed by syngeneic bone marrow transplantation (SBMT) in prevention and treatment of already established CR-EAE. Treatment with TBI and SBMT on day 5 after the induction of CR-EAE, just before the onset of clinical signs, completely inhibited the appearance of the paralytic signs. The same treatment, applied 4 d after the clinical onset of the disease, led to a significant regression of the paralytic signs and to a total inhibition of spontaneous relapses during a follow-up period of 2 mo. Challenge of mice with GMBP+CFA 78 d after the passive induction of CR-EAE induced a relapse of the disease 7 d later in almost all of the untreated mice; in contrast, the same challenge given to TBI+SBMT-treated mice caused a delayed relapse (30 d later) in only a minority (3/7) of the challenged mice. In vitro lymphocytic proliferative responses to GMBP and purified protein derivative were significantly lower in TBI+SBMT-treated mice before and after the GMBP challenge, although these mice were fully immunocompetent, as evidenced by their normal lymphocytic proliferation to concanavalin A (ConA) and the FACS® analysis of their lymphocytic subpopulations. A similar beneficial therapeutic effect was observed in mice treated with CY followed by SBMT, after the onset of CR-EAE. 
Introduction
A chronic relapsing form ofexperimental autoimmune encephalomyelitis (CR-EAE) was induced in SJL/J mice by adoptive transfer of lymph node cells (LNC) sensitized to guinea pig myelin basic protein (GMBP). We examined the efficacy of high dose immunosuppressive regimens (cyclophosphamide ICY] 300 mg/kg or total body irradiation ITBI1 900 cGy) followed by syngeneic bone marrow transplantation (SBMT) in prevention and treatment of already established CR-EAE. Treatment with TBI and SBMT on day 5 after the induction of CR-EAE, just before the onset of clinical signs, completely inhibited the appearance of the paralytic signs. The same treatment, applied 4 d after the clinical onset of the disease, led to a significant regression of the paralytic signs and to a total inhibition of spontaneous relapses during a follow-up period of 2 mo. Challenge of mice with GMBP+CFA 78 d after the passive induction of CR-EAE induced a relapse of the disease 7 d later in almost all of the untreated mice; in contrast, the same challenge given to TBI+SBMT-treated mice caused a delayed relapse (30 d later) in only a minority (3/7) of the challenged mice. In vitro lymphocytic proliferative responses to GMBP and purified protein derivative were significantly lower in TBI+SBMT-treated mice before and after the GMBP challenge, although these mice were fully immunocompetent, as evidenced by their normal lymphocytic proliferation to concanavalin A (ConA) and the FACS® analysis of their lymphocytic subpopulations. A similar beneficial therapeutic effect was observed in mice treated with CY followed by SBMT, after the onset of CR-EAE. Our results could support possible clinical applications of similar therapeutic strategies, involving acute immunosuppression followed by stem cell transplantation and retolerization ofthe reconstituting immune cells in life-threatening neurological and multisystemic autoimmune diseases. (J.
The chronic relapsing form of experimental autoimmune encephalomyelitis (CR-EAE)' in mice is characterized clinically by relapses and remissions ofparalytic signs and pathologically by demyelinating lesions in the white matter of the central nervous system (1) (2) (3) (4) (5) , resembling multiple sclerosis in humans (6) . CR-EAE is induced in SJL/J mice by adoptive transfer of lymphocytes that have been sensitized in vitro to myelin basic protein (MBP) (3) . T cells are crucial for the development of EAE and CR-EAE (7, 8) . T cells of the Lyt-1 phenotype were observed in perivascular cuffs in the brain and spinal cord of animals with EAE (9) , and T cell clones that react with the encephalitogenic determinant ofbasic protein were proved sufficient to induce the disease (10) .
Treatment of the acute form of EAE was previously achieved using several immunosuppressive regimens (1 1-25). Cyclophosphamide (CY) was shown to be a very effective agent for inhibition ofactively and passively induced acute EAE (16) (17) (18) (19) (20) (21) (22) . However, treatment ofCR-EAE requires chronic administration of the cytoreductive drug, and the cessation of treatment is often associated with reappearance of paralytic signs and a severe neurological outcome (19, 20, 22) . Moreover, the chronic treatment is accompanied with acumulative toxic side effects.
Treatment of an ongoing CR-EAE with apparent paralytic signs and histological damage was always a difficult task, especially in the form of CR-EAE passively induced with T cells that were presensitized with MBP and subsequently activated in vitro. Effective inhibition of CR-EAE was accomplished with administration ofanti-CD4 (26-28) monoclonal antibodies, and recently through MBP feeding (29) .
In this study, we tried a different approach to treat adoptively transferred CR-EAE in SJL/J mice: a single application of a high dose of CY or TBI for effective elimination of the autoreactive lymphocytes, followed by bone marrow transplantation obtained from healthy syngeneic donors, to rescue the immunocompromised mice and to provide them with a source of uncommitted lymphoid progenitors for reinduction ofunresponsiveness toward "self." We evaluated the efficacy of this treatment in inhibition of further paralytic relapses and in the induction of antigen-specific tolerance during the process of immune reconstitution. Boston, MA). Cells from each microculture were harvested on fiberglass filters using a multiharvester (Dynatech Laboratories, Alexandria, VA), and the incorporated radioactivity was measured using standard scintillation techniques. The stimulation index (SI) was calculated as follows: mean cpm of cells cultured in the presence of antigen divided by the mean cpm of cells cultured in the absence of antigen.
Analysis ofT lymphocyte populations. Surface markers oflymphocytes from pooled spleen cells obtained from naive mice, untreated mice with CR-EAE, and mice with CR-EAE treated with TBI+SBMT were analyzed. 50 ,d of cell suspension (2 X 10' cells/ml) was mixed with 5 ;d FITC-cohjugated monoclonal anti-CD3, anti-L3T4, or phycoerythrin-conjugated anti-Lyt-2 and anti-IgM antibodies (BectonDickinson, Mountain View, CA) and 45 Ml PBS containing 0.1% sodium azide and 2% FCS. The cell mixture was incubated for 45 min on ice, washed twice, and resuspended in 1 ml of cold medium ( 106/ml).
Positively stained cells were enumerated by a fluorescence-activated cell sorter (FACSO, Becton-Dickinson).
Results
Effect ofacute cytoreductive treatment (TBI or CY)followed by SBMT on the clinical course of CR-EAE. SJL/J mice were treated 5 d after the injection of GMBP-stimulated LNC (2 d before the expected onset of paralysis) with TBI (900 cGy), followed 1 d later by SBMT. As shown in Fig. 1 Cytoreductive treatment with CY (300 mg/kg) followed by SBMT at an early stage ofclinical CR-EAE (immediately after the first clinical signs ofparalysis) inhibited the development of the disease (P < 0.001) (Fig. 2) ; untreated control mice (6/7) progressed to severe paralysis, followed by a relapsing-remitting course. Table I A shows the 2-mo follow-up in both groups; a total number ofseven relapses were observed in the untreated POST ADOPTIVE TRANSFER OF LNC Figure 1 . Prevention of passively induced CR-EAE in SJL/J mice with TBI followed by SBMT. Mice were injected on day 0 with 50 X 106 GMBP-sensitized LNC as described in Methods. On day 5 after the adoptive transfer of LNC, mice were either left untreated or were treated with TBI followed by SBMT (as described in Methods). Mice were examined daily for signs of EAE and scored according to a 0-6 scale of increasing severity of the disease. with a similar mean clinical score and were treated with either CY followed by SBMT (as described in Methods) or left untreated. Mice were examined daily for signs of EAE and scored according to a 0-6 scale of increasing severity of the disease.
group during this period, whereas no relapses were noted in the CY+SBMT-treated group (P < 0.03).
The efficacy of the above treatment was evaluated in mice that had already developed paralytic signs. Mice were treated 3-4 d after the onset of paralysis with either high dose CY or TBI, followed by SBMT. The clinical course of CR-EAE in untreated and in TBI+SBMT-or CY+SBMT-treated mice is presented in Fig. 3 and 4 , respectively. A significant regression ofthe clinical signs (Fig. 3, 4 ) occurred after both cytoreductive regimens regimens (P < 0.001 and P < 0.0001, respectively). Both of these therapeutic interventions also inhibited the appearance of further paralytic relapses. As shown in Table I B, a total of 11 relapses was observed in the seven untreated mice during a period of 2 mo, whereas no relapses occurred in the TBI+SBMT-treated group (P < 0.02). In another experiment (where mice received CY instead of TBI), a total of 19 relapses was observed in the untreated group during a period of 4 mo (Table I C); only 5 relapses occurred in mice treated with CY followed by SBMT (P < 0.03) and the severity of the relapses was milder (mean maximal score:3. 1 in untreated and 1.9 in the CY+SBMT-treated mice, P < 0.03) (Table I C). The longlasting effect of SBMT treatment was evaluated by challenging the treated mice with a subcutaneous injection of GMBP in CFA 72 d after the transfer of the GMBP-sensitized lymphocytes. This immunologic challenge induced a severe paralytic relapse in six of seven (86%) untreated control mice 7 d later (Fig. 3) ; only three ofthe seven TBI+SBMT-treated mice developed paralytic signs with a delay of 30 d, after the GMBP injection (Table I B, Fig. 3 In vitro proliferative responses ofLNC to GMBP and PPD. LNC obtained (60 d after the SBMT) from control mice suffering from CR-EAE displayed a clear proliferative response to GMBP and PPD 78 d after the adoptive transfer ofGMBP-sensitized LNC (Table II A) . In contrast, LNC from mice similarly injected with GMBP-specific lymphocytes and treated with TBI+SBMT showed a weaker response to the same antigens (GMBP and PPD) (P < 0.01) ( Table II A) .
Immunologic challenge of the untreated mice with GMBP enhanced the proliferative response to GMBP and PPD (examined 10 d later) (Table II B) . The in vitro reactivity of lymphocytes from mice with CR-EAE treated with TBI+SBMT and similarly challenged with GMBP remained lower (P < 0.01) ( Table II B) . This finding may be attributed to either active suppression ofthe autoimmune clones or generalized immunological anergy after SBMT, since the ConA-induced proliferation was also reduced. Similar results were obtained in mice treated with CY+SBMT (data not shown). Analysis of lymphocyte subpopulations. Spleen cells obtained from untreated and TBI+SBMT-treated mice with CR-EAE were examined by FACS® analysis for the expression of CD3, L3T4, Lyt-2, and IgM surface markers, 78 d after the induction of CR-EAE. ter were seen (Fig. 6A ). Luxol fast blue staining revealed large areas of demyelination around the infiltrations (Fig. 6 A) . In brain sections from mice treated with TBI and SBMT, the number and the severity of lesions were significantly reduced (Fig.  6 , B and C). Similar amelioration ofthe central nervous system (CNS) pathology was observed in mice treated with CY followed by SBMT (data not shown).
Discussion
In this study, which represents an extension ofour initial observation on the beneficial role of acute cytoreductive treatment combined with SBMT on acute EAE (31), we have documented that high dose CY or TBI followed by SBMT can inhibit and even reverse already clinically established CR-EAE, induced by adoptive transfer of MBP-sensitized lymphocytes in SJL/J mice. This treatment also prevented the appearance of paralytic relapses and induced immunological unresponsiveness to the relevant immunizing antigens GMBP and PPD. (10, 36, 37) ; therefore this procedure has been used as a pretreatment of recipient mice before injection of LNC, to accelerate the development of the disease (EAE) (10, 36, 37 (26) . Interestingly, a more aggressive immunosuppression followed by SBMT, applied at an early stage of the disease after the onset of the first signs of CR-EAE, can either totally inhibit or reverse the development of the disease. We have also shown that only a few spontaneous relapses occurred in treated mice. When untreated mice with CR-EAE were challenged with GMBP in CFA 72 d after the injection of the MBP-sensitized lymphocytes, they developed a severe relapse (Table I B) , while only three of the seven mice treated with TBI+SBMT and similarly rechallenged with GMBP displayed paralytic signs; in addition, this paralytic relapse in the TBI+SBMT-treated mice occurred after a delay of> 30 d after the GMBP inoculation (Fig. 3, Table I B). Our data are compatible with either one ofthe following interpretations: (a) development of partial anergy/tolerance to GMBP, as may be supported by the specific reduction of the in vitro proliferative responses of lymphocytes to GMBP and PPD (Table II) ; and/ or (b) the existence of an antiidiotypic network similar to that reported in other studies, after injection of irradiated GMBPspecific lymphocytes (42 .A (C) Small lymphocytic infiltration into the cerebellar subcortical white matter of mice treated with TBI and SBMT (hematoxylin/eosin). 770 Karussis et al. Overall, results presented here show that this combined treatment of high dose acute immunosuppression followed by syngeneic BMT, which represents the experimental equivalent of autologous BMT, not only reverses already established CR-EAE but also results in long-term beneficial effects by inhibiting or ameliorating the paralytic relapses. Based on our experimental model, possible application of similar therapeutic approaches should be considered for life-threatening human neurological and other systemic autoimmune diseases.
